WP
TVRD

Woodline Partners’s Tvardi Therapeutics TVRD Stock Holding History

Woodline Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,538
Closed -$1.79M – 770
2023
Q2 		$1.79M Buy
17,538
+16,357
+1,385% +$2.25M 0.02% 442
2023
Q1 		$209K Buy
+1,181
New +$395K ﹤0.01% 584

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Woodline Partners's TVRD Position: Q3 2023 in Review

Woodline Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 17,538 shares — an estimated $1.79M sold.

Woodline Partners first reported a position in TVRD in Q1 2023 and held it in 2 quarters. The position peaked at $1.79M in Q2 2023. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • Woodline Partners reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Woodline Partners sold 17,538 Tvardi Therapeutics shares in Q3 2023, an estimated $1.79M.
  • Woodline Partners first reported a position in Tvardi Therapeutics in Q1 2023 and held it in 2 quarters.
  • Woodline Partners's Tvardi Therapeutics position peaked at $1.79M in Q2 2023.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.